In a major advancement for global HIV prevention, the World Health Organisation (WHO) has officially recommended injectable ...

Kenya is one of nine African countries selected for the initial rollout of lenacapavir (LEN), a new injectable drug for human ...

Gilead Sciences, Inc. (NASDAQ:GILD) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Gilead Sciences, Inc.

A newly approved HIV medication provides near-total protection against infection with just two injections a year. It's called Lenacapavir. But the high price of the drug could limit its reach.

Access is the central tenet to the success of lenacapavir as a form of preexposure prophylaxis (PrEP), according to Jeremiah Johnson, the executive director of PrEP4All and Mitchell Warren, the ...

Gilead's drug lenacapavir (marketed under the name Yeztugo) is a long-acting, pre-exposure prophylaxis (PrEP), meaning it helps prevent HIV infection in people who are HIV-negative but at risk.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion under accelerated ...

Another study of more than 3,000 people found just two cases of HIV among the lenacapavir cohort. Here's Onyema Ogbuagu, an infectious disease researcher at Yale who ran one of the studies.